Your request goes to Bertis Inc.. Follow up with them in Messages on Global Trade Plaza.
MastoCheck is a blood test that can easily screen for breast cancer at an early stage. Breast cancer is diagnosed early by substituting the quantitative values of three types of protein biomarkers in the blood, which are closely related to breast cancer, into a unique, patented algorithm. An innovative and convenient test method that detects early breast cancer with an accuracy of 92% (based on the patent) by using only a very small amount of blood. Bertis has developed multiple markers that can detect early breast cancer with an accuracy of 92% through identification of multiple proteins that are expressed sensitively in early-stage breast cancer and combination of certain proteins that demonstrated high accuracy and reproducibility among these combinations. DEVELOPMENT PROCESS: - MASTOCHECK was developed by a team led by Professor Dong-Young Noh, a world-renowned authority on breast cancer, of Seoul National University. - After analyzing approximately 600,000 proteins and selecting 3 markers exhibiting optimal accuracy, the highest accuracy was obtained by adding Bertis�¢?? own algorithm that enhances accuracy. - After several years of repeated validation work, a medical device product license was obtained from the MFDS in January 2019. To date (as of September 2023), MASTOCHECK has been introduced to about 400 hospitals and screening institutions nationwide, with priority given to large screening institutions.
Describe what you need once. Suppliers who deal in it see your requirement as a buy lead and can send you offers.
MASTOCHECK is a blood test for early breast cancer screening that measures three protein biomarkers and applies a patented algorithm to deliver a result. The test requires only a small blood volume and is reported to achieve 92% accuracy based on the patent.
Development was led by Professor Dong-Young Noh of Seoul National University after analysis of roughly 600,000 proteins to select the three markers. A medical device product license was granted by the MFDS in January 2019, and by September 2023 the test had been adopted by about 400 hospitals and screening institutions in South Korea.
The seller has not added a specification yet; ask for the data sheet or test certificate. Ask Bertis Inc. for a firm quote and delivery terms before you order.
Bertis Inc. is a B2B supplier based in South Korea (Republic Of Korea), listed on Global Trade Plaza since October 2026. Use Inquire now or Chat with supplier to ask Bertis Inc. for prices, specifications and documents for MASTOCHECK Breast Cancer Early Diagnosis.
Ask Bertis Inc. which payment terms they accept for MASTOCHECK Breast Cancer Early Diagnosis. Agree the payment terms in writing with the supplier before you pay.
Placing an order for MASTOCHECK Breast Cancer Early Diagnosis with Bertis Inc. is quick and straightforward on Global Trade Plaza, a leading B2B marketplace for global buyers and suppliers. You can:
When purchasing MASTOCHECK Breast Cancer Early Diagnosis from a B2B marketplace in 2025, focus on the following critical factors:
Comparing prices and communicating directly with Bertis Inc. can help ensure value for money and better sourcing decisions.
Global Trade Plaza is home to B2B buyers, wholesalers, distributors, and importers of MASTOCHECK Breast Cancer Early Diagnosis across industries and countries. To discover the most active and high-value buyers:
Bertis Inc., a B2B supplier from South Korea (Republic Of Korea), dispatches MASTOCHECK Breast Cancer Early Diagnosis primarily through the port at South Korea (Republic Of Korea). Packaging types (e.g., bulk, custom, eco-friendly) and estimated pricing may vary based on order volume and destination. To get detailed logistics and pricing information, use Get a quote or Chat with supplier, or Sign Up for direct supplier interaction.